Haloperidol News and Research

RSS

Haloperidol is a typical antipsychotic. It is in the butyrophenone class of antipsychotic medications and has pharmacological effects similar to the phenothiazines.

Hyperion Therapeutics commences enrollment in its HPN-100 episodic hepatic encephalopathy trial

Hyperion Therapeutics, Inc. today announced that the first patient has been enrolled in its phase II clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate).

3 Dec 2009

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Novartis announced today that new data, including a late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a form of chronic myeloid leukemia, demonstrate the strength of the company's hematology portfolio in advancing the care of patients.

2 Dec 2009

Hyperion Therapeutics enrolls first patient in HPN-100 phase III clinical trial for urea cycle disorders

Hyperion Therapeutics today announced that the first patient has been enrolled in its pivotal phase III clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate). The 4-week, multi-center, randomized, double-blind, cross-over study is designed to evaluate the non-inferiority of glycerol phenylbutyrate to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder in adults with urea cycle disorders.

27 Oct 2009

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Novartis announced today that Tasigna (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna was well tolerated in the study.

20 Oct 2009

Hyperion enrolls first patient in HPN-100 investigational compound clinical trial

Hyperion Therapeutics today announced that the first patient has been enrolled in a clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate) in children ages 6-17 with urea cycle disorders (UCD). The study will evaluate the safety, tolerability, and ammonia control of glycerol phenylbutyrate compared to BUPHENYL® (sodium phenylbutyrate).

15 Sep 2009

Mylan receives FDA approval for additional strengths of antipsychotic Haloperidol

Mylan Inc. has announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Haloperidol Tablets USP, 10 mg and 20 mg. These strengths are in addition to Mylan's currently marketed 0.5 mg, 1 mg, 2 mg and 5 mg strengths of the product.

20 Jul 2009

Antipsychotic drugs get FDA label changes

The U.S. Food and Drug Administration today exercised its new authority under the Food and Drug Administration Amendments Act of 2007 (FDAAA) to require manufacturers of "conventional" antipsychotic drugs to make safety-related changes to prescribing information, or labeling, to warn about an increased risk of death associated with the off-label use of these drugs to treat behavioral problems in older people with dementia.

16 Jun 2008

Treatment with an anti-psychotic drug found to cause changes in metabolism earlier than expected

Schizophrenia is a complex type of psychotic mental illness characterized by thoughts that are uncoupled from reality.

8 Apr 2008

Aripiprazole has potential for treating alcohol dependence

Aripiprazole is currently approved to treat bipolar disorder as well as schizophrenia. A new study has found that it significantly and dose-dependently increases the sedative effects of alcohol and, to a lesser degree, decreases the euphoric effects of alcohol. Future research will need to examine the beneficial versus the side effects of aripiprazole for treatment of alcohol dependence.

4 Apr 2008

Placebo better than antipsychotic drugs for treating aggression in the intellectually disabled

Antipsychotic drugs which are commonly used to treat aggression in people who are intellectually disabled have been revealed to be ineffective.

6 Jan 2008

Common antipsychotic drug for methamphetamine overdose may damage brain cells

A common antipsychotic drug used in emergency rooms to treat methamphetamine overdose damages nerve cells in an area of the brain known to regulate movement, a new study shows.

30 May 2007

Drugs that adjust dopamine levels in the brain greatly affect how people react to success and failure

In a first-of-its-kind study on humans, researchers measured how dopamine-related drugs affect the striatum, a part of the brain that is stimulated by rewards.

27 Apr 2007

Depression linked with a specific autoantibody and central nervous system dysfunction in lupus

Systemic lupus erythomatosus (SLE), often simply called lupus, is a complex autoimmune disease marked by joint pain, skin rashes, extreme fatigue, and depression, among other symptoms.

27 Feb 2007

FDA warns consumers about buying medications over the Internet

The Food and Drug Administration (FDA) in the United States has again warned consumers about buying medications over the Internet.

19 Feb 2007

Tetrabenazine cuts down involuntary movements in Huntington's disease

The medication tetrabenazine cut down involuntary movement in patients with Huntington's disease on average by about 25 percent, with many patients experiencing a greater improvement, according to a study in the February 14 issue of the journal Neurology.

17 Feb 2006

Link between cat faeces and schizophrenia

Researchers have found stronger evidence for a link between a parasite in cat faeces and undercooked meat and an increased risk of schizophrenia.

18 Jan 2006

Study of the effects of aripiprazole, olanzapine, quetiapine and risperidone, in elderly patients with dementia

Some newer antipsychotic medications may be associated with a small increased risk of death when used to treat elderly dementia patients, psychiatrists at Johns Hopkins warn.

18 Oct 2005

Commonly used drugs raise the risk of cardiac problems

As many as 15,000 sudden deaths each year in Europe and the U.S., may be caused by drugs commonly prescribed for psychiatric and gut disorders.

11 May 2005

Increased risk of sudden cardiac death from some non-cardiac drugs

Non-cardiac drugs that interfere with the electrical activity controlling the heartbeat are associated with a three-fold risk of sudden cardiac death, according to Dutch research published (Wednesday 11 May) in Europe's leading cardiology journal, the European Heart Journal.